Revenue: As of FY2025 Q2, the actual value is USD 7.475 K.EPS: As of FY2025 Q2, the actual value is USD -0.97.EBIT: As of FY2025 Q2, the actual value is USD -1.679 M.<h3>Segment Revenue</h3><ul><li>Product Test Sales: Revenue for the six months ended June 30, 2025, was $8,415, compared to $23,798 for the same period in 2024. For the three months ended June 30, 2025, revenue was $7,475, compared to $7,870 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the six months ended June 30, 2025, the net loss was - $3,318,263, compared to - $5,451,579 for the same period in 2024. For the three months ended June 30, 2025, the net loss was - $1,683,199, compared to - $1,287,995 for the same period in 2024.</li><li>Operating Expenses: Selling, general, and administrative expenses for the six months ended June 30, 2025, were $3,317,674, compared to $5,464,306 for the same period in 2024. For the three months ended June 30, 2025, these expenses were $1,686,174, compared to $1,290,330 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was - $2,971,566, compared to - $2,443,450 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used in investing activities was - $83,132, compared to - $271,010 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $3,193,711, compared to $2,741,056 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Cardio Diagnostics Holdings, Inc. plans to develop additional products, including clinical tests for stroke, congestive heart failure, and diabetes. The company aims to expand the adoption of its products across key channels, including health systems and self-insured employers, and leverage newly awarded CPT PLA codes to expand reimbursement efforts.</li><li>Non-Core Business: The company is exploring additional market opportunities in the US and internationally and pursuing potential strategic partnerships and acquisitions of synergistic companies.</li></ul>

CARDIO DIAGNOSTICS HOLDINGS INC C/WTS (10/25/2027) TO PUR COM | 10-Q: FY2025 Q2 Revenue: USD 7.475 K